Richard A Hopkins1, Arthur A Bert2, Stephen L Hilbert3, Rachael W Quinn3, Kathleen M Brasky4, William B Drake3, Gary K Lofland3. 1. Cardiac Regenerative Surgery Research Laboratories, The Ward Family Center for Congenital Heart Disease, Children's Mercy Hospital, Kansas City, Mo. Electronic address: rahopkins@cmh.edu. 2. Cardiac Regenerative Surgery Research Laboratories, The Ward Family Center for Congenital Heart Disease, Children's Mercy Hospital, Kansas City, Mo; Department of Surgery (Division of Cardiac Anesthesiology), Warren Alpert School of Medicine, Brown University, Providence, RI. 3. Cardiac Regenerative Surgery Research Laboratories, The Ward Family Center for Congenital Heart Disease, Children's Mercy Hospital, Kansas City, Mo. 4. Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, Tex.
Abstract
OBJECTIVE: This study assesses in a baboon model the hemodynamics and human leukocyte antigen immunogenicity of chronically implanted bioengineered (decellularized with collagen conditioning treatments) human and baboon heart valve scaffolds. METHODS: Fourteen baboons underwent pulmonary valve replacement, 8 with decellularized and conditioned (bioengineered) pulmonary valves derived from allogeneic (N = 3) or xenogeneic (human) (N = 5) hearts; for comparison, 6 baboons received clinically relevant reference cryopreserved or porcine valved conduits. Panel-reactive serum antibodies (human leukocyte antigen class I and II), complement fixing antibodies (C1q binding), and C-reactive protein titers were measured serially until elective sacrifice at 10 or 26 weeks. Serial transesophageal echocardiograms measured valve function and geometry. Differences were analyzed with Kruskal-Wallis and Wilcoxon rank-sum tests. RESULTS: All animals survived and thrived, exhibiting excellent immediate implanted valve function by transesophageal echocardiograms. Over time, reference valves developed a smaller effective orifice area index (median, 0.84 cm(2)/m(2); range, 1.22 cm(2)/m(2)), whereas all bioengineered valves remained normal (effective orifice area index median, 2.45 cm(2)/m(2); range, 1.35 cm(2)/m(2); P = .005). None of the bioengineered valves developed elevated peak transvalvular gradients: 5.5 (6.0) mm Hg versus 12.5 (23.0) mm Hg (P = .003). Cryopreserved valves provoked the most intense antibody responses. Two of 5 human bioengineered and 2 of 3 baboon bioengineered valves did not provoke any class I antibodies. Bioengineered human (but not baboon) scaffolds provoked class II antibodies. C1q(+) antibodies developed in 4 recipients. CONCLUSIONS: Valve dysfunction correlated with markers for more intense inflammatory provocation. The tested bioengineering methods reduced antigenicity of both human and baboon valves. Bioengineered replacement valves from both species were hemodynamically equivalent to native valves.
OBJECTIVE: This study assesses in a baboon model the hemodynamics and human leukocyte antigen immunogenicity of chronically implanted bioengineered (decellularized with collagen conditioning treatments) human and baboon heart valve scaffolds. METHODS: Fourteen baboons underwent pulmonary valve replacement, 8 with decellularized and conditioned (bioengineered) pulmonary valves derived from allogeneic (N = 3) or xenogeneic (human) (N = 5) hearts; for comparison, 6 baboons received clinically relevant reference cryopreserved or porcine valved conduits. Panel-reactive serum antibodies (human leukocyte antigen class I and II), complement fixing antibodies (C1q binding), and C-reactive protein titers were measured serially until elective sacrifice at 10 or 26 weeks. Serial transesophageal echocardiograms measured valve function and geometry. Differences were analyzed with Kruskal-Wallis and Wilcoxon rank-sum tests. RESULTS: All animals survived and thrived, exhibiting excellent immediate implanted valve function by transesophageal echocardiograms. Over time, reference valves developed a smaller effective orifice area index (median, 0.84 cm(2)/m(2); range, 1.22 cm(2)/m(2)), whereas all bioengineered valves remained normal (effective orifice area index median, 2.45 cm(2)/m(2); range, 1.35 cm(2)/m(2); P = .005). None of the bioengineered valves developed elevated peak transvalvular gradients: 5.5 (6.0) mm Hg versus 12.5 (23.0) mm Hg (P = .003). Cryopreserved valves provoked the most intense antibody responses. Two of 5 human bioengineered and 2 of 3 baboon bioengineered valves did not provoke any class I antibodies. Bioengineered human (but not baboon) scaffolds provoked class II antibodies. C1q(+) antibodies developed in 4 recipients. CONCLUSIONS:Valve dysfunction correlated with markers for more intense inflammatory provocation. The tested bioengineering methods reduced antigenicity of both human and baboon valves. Bioengineered replacement valves from both species were hemodynamically equivalent to native valves.
Authors: Jesper Hjortnaes; Carlijn V C Bouten; Lex A Van Herwerden; Paul F Gründeman; Jolanda Kluin Journal: Tissue Eng Part B Rev Date: 2009-09 Impact factor: 6.389
Authors: Richard A Hopkins; Alyce Linthurst Jones; Lloyd Wolfinbarger; Mark A Moore; Arthur A Bert; Gary K Lofland Journal: J Thorac Cardiovasc Surg Date: 2009-02-23 Impact factor: 5.209
Authors: William A Zoghbi; John B Chambers; Jean G Dumesnil; Elyse Foster; John S Gottdiener; Paul A Grayburn; Bijoy K Khandheria; Robert A Levine; Gerald Ross Marx; Fletcher A Miller; Satoshi Nakatani; Miguel A Quiñones; Harry Rakowski; L Leonardo Rodriguez; Madhav Swaminathan; Alan D Waggoner; Neil J Weissman; Miguel Zabalgoitia Journal: J Am Soc Echocardiogr Date: 2009-09 Impact factor: 5.251
Authors: Emanuela S Fioretta; Sarah E Motta; Valentina Lintas; Sandra Loerakker; Kevin K Parker; Frank P T Baaijens; Volkmar Falk; Simon P Hoerstrup; Maximilian Y Emmert Journal: Nat Rev Cardiol Date: 2020-09-09 Impact factor: 32.419
Authors: John D Vossler; Young Min Ju; J Koudy Williams; Steven Goldstein; James Hamlin; Sang Jin Lee; James J Yoo; Anthony Atala Journal: Biomed Mater Date: 2015-09-03 Impact factor: 3.715
Authors: Arthur A Bert; William B Drake; Rachael W Quinn; Kathleen M Brasky; James E O'Brien; Gary K Lofland; Richard A Hopkins Journal: Prog Pediatr Cardiol Date: 2013-08-01
Authors: Anneke Neumann; Samir Sarikouch; Thomas Breymann; Serghei Cebotari; Dietmar Boethig; Alexander Horke; Philipp Beerbaum; Mechthild Westhoff-Bleck; Harald Bertram; Masamichi Ono; Igor Tudorache; Axel Haverich; Gernot Beutel Journal: Tissue Eng Part A Date: 2014-01-24 Impact factor: 3.845